Brief: Ultragenyx And Mereo Biopharma Announce Interim Phase 2 Data From Phase 2/3 Orbit Study Demonstrating Setrusumab (Ux143) Significantly Reduced Fracture Rates In Patients With Osteogenesis Imperfecta

Mereo BioPharma

14/10/2023 21:35

Oct 14 (Reuters) - Ultragenyx Pharmaceutical:
    * ULTRAGENYX AND MEREO BIOPHARMA ANNOUNCE INTERIM PHASE 2
DATA
FROM PHASE 2/3 ORBIT STUDY DEMONSTRATING SETRUSUMAB (UX143)
SIGNIFICANTLY REDUCED FRACTURE RATES IN PATIENTS WITH
OSTEOGENESIS IMPERFECTA (OI)
    * ULTRAGENYX -PHASE 2 DATA SHOW TREATMENT WITH SETRUSUMAB
RESULTED
IN 67% REDUCTION IN ANNUALIZED FRACTURE RATE ASSOCIATED WITH
IMPROVEMENTS IN BMD
    * ULTRAGENYX PHARMACEUTICAL SAYS PHASE 3 PORTION OF STUDY IS
CURRENTLY ENROLLING APPROXIMATELY 195 PATIENTS AT 50 SITES
ACROSS 12 COUNTRIES
    * ULTRAGENYX PHARMACEUTICAL SAYS AS OF DATA CUT-OFF, THERE
WERE NO
TREATMENT-RELATED SERIOUS ADVERSE EVENTS OBSERVED IN STUDY

Source text for Eikon:  ID:nGNXbm1XPY 
Further company coverage:  MAH0y.F 

 ((Reuters.Briefs@thomsonreuters.com;))